AI-Driven Marketplaces Reviving Shelved Cell and Gene Therapies
In recent years, hundreds of promising cell and gene therapy (CGT) candidates have been abandoned not because they failed clinically, but because traditional commercial models could not justify their development costs. The American Society of Gene and Cell Therapy (ASGCT) and the Orphan Therapeutics Accelerator (OTXL) responded to this gap by launching CGTxchange, a joint‑ownership clearinghouse that pairs an AI‑enabled evaluation platform with ASGCT’s global network. The marketplace scans clinical‑stage CGTs that have been deprioritized, scores them against a set of scientific and economic criteria, and then matches the most viable assets with investors or development partners willing to assume the remaining risk. By leveraging AI to surface hidden value, CGTxchange creates an alternative pathway for ultra‑rare disease programs that were sidelined after policy shifts—such as tighter Medicare price‑negotiation rules—reduced the expected return on investment.
Parallel to this marketplace evolution, DeepMind’s AlphaFold continues to reshape the broader drug discovery landscape. Since its 2024 Nobel‑winning breakthrough, AlphaFold has become a foundational tool for more than three million researchers worldwide, delivering high‑accuracy protein‑structure predictions that accelerate target identification and validation. In 2026, DeepMind CEO Demis Hassabis emphasized that AlphaFold represents only the first rung of an AI‑powered scientific revolution, with his spin‑out Isomorphic Labs already converting structural insights into pre‑clinical drug candidates. The company’s pipeline, slated for first‑in‑human trials by the end of 2026, demonstrates how generative AI can move beyond data generation to tangible therapeutic development, even as Hassabis warns that the commercial hype around generative AI may temporarily slow deeper scientific progress.
The convergence of AI‑driven evaluation platforms like CGTxchange and advanced protein‑modeling tools such as AlphaFold signals a new era for orphan and rare‑disease therapeutics. By systematically re‑examining shelved CGTs, AI can uncover viable pathways that were previously hidden by opaque financial models, while AlphaFold’s structural insights reduce the time and cost of early‑stage discovery. Together, these innovations promise to unlock a pipeline of treatments that address unmet medical needs, attract new sources of capital, and ultimately bring life‑changing therapies to patients who have been left behind by conventional drug‑development economics.
